Skip to main content

Advertisement

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Comparison of vilanterol, a novel long-acting beta2 agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids

  • Jan Lötvall1Email author,
  • Eric D Bateman2,
  • William W Busse3,
  • Paul M O’Byrne4,
  • Ashley Woodcock5,
  • William T Toler6,
  • Loretta Jacques7,
  • Caroline Goldfrad8 and
  • Eugene R Bleecker9
Journal of Negative Results in BioMedicine201413:9

https://doi.org/10.1186/1477-5751-13-9

Received: 19 June 2013

Accepted: 14 May 2014

Published: 13 June 2014

Back to article

Open Peer Review reports

Pre-publication versions of this article and author comments to reviewers are available by contacting info@biomedcentral.com.

Original Submission
19 Jun 2013 Submitted Original manuscript
2 Dec 2013 Reviewed Reviewer Report - David Price
8 Dec 2013 Reviewed Reviewer Report - Leif Bjermer
24 Apr 2014 Author responded Author comments - Jan Lotvall
Resubmission - Version 2
24 Apr 2014 Submitted Manuscript version 2
13 May 2014 Author responded Author comments - Jan Lotvall
Resubmission - Version 3
13 May 2014 Submitted Manuscript version 3
Publishing
14 May 2014 Editorially accepted
13 Jun 2014 Article published 10.1186/1477-5751-13-9

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting info@biomedcentral.com. All previous versions of the manuscript and all author responses to the reviewers are also available.

You can find further information about the peer review system here.

Authors’ Affiliations

(1)
Krefting Research Centre, University of Gothenburg
(2)
Department of Medicine, University of Cape Town
(3)
Department of Medicine, University of Wisconsin
(4)
Michael G DeGroote School of Medicine, McMaster University
(5)
Institute of Inflammation and Repair, University of Manchester, University Hospital of South Manchester
(6)
Respiratory Medicines Development Center, GlaxoSmithKline
(7)
Respiratory Medicines Development Centre, GlaxoSmithKline
(8)
Quantitative Sciences Division, GlaxoSmithKline
(9)
Center for Genomics and Personalized Medicine, Wake Forest University School of Medicine

Advertisement